(Press-News.org) As adoption of Continuous Glucose Monitoring (CGM) continues to increase, there is a growing body of evidence supporting the use of this technology in improving diabetes outcomes for patients with Type 1 or Type 2 Diabetes. A new supplement in the peer-reviewed journal Diabetes Technology & Therapeutics (DTT) provides an excellent perspective of the past, present, and future of CGM. Click here to read the supplement now.
In the supplement Rickson et al. review the rapid pace in which diabetes technology has progressed and the implications for relying on rigorous and extensive timelines to publish randomized controlled trials to impact provider awareness, clinical practice guidelines and insurance coverage. They propose alternative approaches to assessing the safety and efficacy of CGMs.
Gavin and Bailey review findings from recent real-world studies, highlighting the obstacles to access CGM and other technologies. They provide an update on current real-world observational prospective studies that demonstrate the clinical efficacy and economic impact of CGM within various diabetes populations in real-world settings.
Munshi et al. demonstrated that older adults with Type 1 diabetes (T1D) who use newer diabetes-related technologies such as CGM had better glycemic control, lower hypoglycemia risk, and fewer glycemic excursions. In the supplement, Munshi reviews the unique needs of older adults with diabetes and provides recommendations for how different types of CGM systems can be used strategically to improve patient care.
Miller and Polonsky discuss the benefits and feasibility of utilizing CGM to encourage lifestyle changes in individuals with prediabetes to prevent their progression to Type 2 diabetes (T2D).
“Our predictions are that CGM will pretty much replace SMBG [self-monitoring of blood glucose] for insulin-requiring patients with diabetes, assuming cost is not a barrier,” states Satish Garg, MD, Editor-in-Chief of Diabetes Technology & Therapeutics, and Professor, University of Colorado Denver, Barbara Davis Center for Diabetes. “CGM will also become the standard for managing T2D, irrespective of the treatment regimen, and the potential of detecting prediabetes (both T1D and T2D) at an early stage so that necessary management can be implemented early.”
This supplement was produced through an unrestricted educational grant from Abbott’s diabetes care business.
About the Journal
Diabetes Technology & Therapeutics (DTT) is a monthly peer-reviewed journal that covers new technology and new products for the treatment, monitoring, diagnosis, and prevention of diabetes and its complications. Led by Editor-in-Chief Satish Garg, MD, University of Colorado Denver, Barbara Davis Center for Childhood Diabetes, the Journal covers breakthrough technologies and new therapeutic drug classes, behavioral aspects and approaches to diabetes care, and the latest advancements and applications of new and emerging technologies including continuous glucose monitoring, alternate insulin delivery methods, artificial pancreas, telemedicine and computerized case management, new insulins with ultra-rapid onset of action, and detection and prevention of hypoglycemia. Tables of contents and a free sample issue may be viewed on the Diabetes Technology & Therapeutics (DTT) website. DTT is the official journal of the International Conference on Advanced Technologies & Treatments for Diabetes (ATTD).
About the Publisher
Mary Ann Liebert, Inc. is a global media company dedicated to creating, curating, and delivering impactful peer-reviewed research and authoritative content services to advance the fields of biotechnology and the life sciences, specialized clinical medicine, and public health and policy. For complete information, please visit the Mary Ann Liebert, Inc. website.
END
The advances and promise of continuous glucose monitoring in diabetes management
2023-06-13
[Attachments] See images for this press release:
ELSE PRESS RELEASES FROM THIS DATE:
Ochsner Health names new chief financial officer and treasurer
2023-06-13
NEW ORLEANS, La. – Ochsner Health has named Jim Molloy as the organization’s next Executive Vice President, Chief Financial Officer and Treasurer. A leader at Citi bringing decades of extensive experience in healthcare finance, Molloy will oversee the organization’s accounting, financial planning and analysis, reimbursement and revenue cycle functions, as well as managed care contracting and treasury. He will also play a pivotal role in the continued development and execution of ...
Low birthweight is independently linked to increased risk of type 2 diabetes, and a particular presentation including lower age at diagnosis
2023-06-13
T2D patients with lower birthweight also show higher use of diabetes drugs than those with normal birthweight, and a larger number of comorbidities including high blood pressure, at the time of diagnosis.
The first study is by Dr Rasmus Wibaek, Steno Diabetes Center Copenhagen, Herlev, Denmark, and Dr Allan Vaag, Steno Diabetes Center Copenhagen, and also Lund University, Malmö, Sweden, and colleagues.
This study included adults aged 30–60 years enrolled in the Danish Inter99 cohort in 1999–2001 (baseline examination), with information on birthweight from original birth records from 1939–1971 and without diabetes at baseline. Birth records were linked ...
Gentle cleansers kill viruses as effectively as harsh soaps, study finds
2023-06-13
Gentle cleansers are just as effective in killing viruses – including coronavirus – as harsh soaps, according to a new study from scientists at the University of Sheffield
Healthcare professionals often substitute alcohol-based hand sanitisers and harsh soaps for skin-friendly cleansers in order to treat or prevent irritant contact dermatitis, which develops when chemical or physical agents damage the skin surface faster than the skin can repair
Incidence and severity of irritant contact dermatitis increased from 20 per cent to 80 per cent amongst healthcare professionals during the Covid-19 pandemic
Researchers also found non-enveloped ...
LP-284 targets non-Hodgkin's lymphoma and DNA damage repair deficiency
2023-06-12
“[...] we demonstrated the new acylfulvene compound LP-284 has anti-tumor activity including nanomolar potency in fifteen in vitro NHL cell lines and in vivo preclinical NHL models.”
BUFFALO, NY- June 12, 2023 – A new research paper was published in Oncotarget's Volume 14 on June 12, 2023, entitled, “LP-284, a small molecule acylfulvene, exerts potent antitumor activity in preclinical non-Hodgkin's lymphoma models and in cells deficient in DNA damage repair.”
Despite advances in therapies treating non-Hodgkin’s ...
Damon Runyon Cancer Research Foundation announces three recipients of 2023 Physician-Scientist Training Award
2023-06-12
Three scientists with exceptional promise and novel approaches to fighting cancer have been named the 2023 recipients of the Damon Runyon Physician-Scientist Training Award. The awardees were selected through a highly competitive and rigorous process by a scientific committee comprised of leading cancer researchers who are themselves physician-scientists.
Physician-scientists are uniquely positioned to translate scientific discoveries into therapies that improve and prolong the lives of their patients. However, ...
Where there’s smoke are lessons in demands of global sustainability
2023-06-12
As the world struggles for sustainability in the face of climate change, wildfire smoke becomes a lesson in how people can become victims far from the root of a problem and far from their control.
In this month’s open access National Science Review, Jianguo “Jack” Liu, MSU Rachel Carson Chair in Sustainability, makes a case for the world to shake off the constraints of traditional governance, which tends to address issues in one place without considering how people or ecologies near and far might be impacted.
Justice at a global scale can be threatened when natural events or human decisions in one part of the world to protect, reroute, ...
Dartmouth-led project updates smoking as a risk factor in NCI mortality estimates
2023-06-12
New findings from a project led by researchers at Dartmouth’s Geisel School of Medicine in collaboration with the National Cancer Institute (NCI) and published in the journal JAMA Network Open, show the dramatic impact that smoking status has on mortality and more accurately predict the risk of dying from cancer and other diseases.
“Historically, mortality risk has often been presented by age, sex, and race but it rarely has accounted for smoking status—a major risk factor for many causes of death,” says lead author Steven Woloshin, MD, MS, a professor of ...
Victor J. Torres, Ph.D., named chair of newly formed Department of Host-Microbe Interactions at St. Jude Children’s Research Hospital
2023-06-12
(MEMPHIS, Tenn., June 12, 2023) St. Jude Children’s Research Hospital today announced that Victor J. Torres, Ph.D., an internationally renowned microbiologist and immunologist has been selected as the inaugural chair of a new Department of Host-Microbe Interactions. This department will establish a world-leading effort focused on exploring the fundamental biology of the interaction of infectious agendas with the human host. The discoveries made through this new effort will advance our ability to more effectively treat, as well as prevent infectious diseases
“Infectious diseases remain one of the leading causes of death globally for children under the age of five,” ...
Digital divide hinders rural innovation, study shows
2023-06-12
UNIVERSITY PARK, Pa. — Cloud-based computing directly contributes to business innovation, but rural businesses lacking sufficient broadband capacity to access cloud services are missing out on their innovation-boosting potential, according to a team of researchers from Penn State and the National Science Foundation. The findings can be used by policymakers and business-support organizations to foster greater opportunities for rural innovation.
“Innovation plays a critical role in keeping businesses competitive and viable, and in turn, healthy businesses are essential to vibrant rural economies. Therefore, we’re interested ...
Penile HIV infection is effectively prevented by antiretroviral treatment
2023-06-12
Of the 38 million people worldwide living with HIV, approximately 700,000 are newly infected men, primarily via sexual transmission. Sexually transmitted HIV infections in exclusively heterosexual men are acquired through the penis. In addition, semen which is produced in the male genital tract (MGT) has been recognized as the primary vector for vaginal and rectal HIV transmission. Notably, the risk of sexual HIV transmission increases with the presence of a concurrent sexually transmitted infection.
For the majority of patients, antiretroviral therapy (ART) rapidly decreases the viral load in blood and semen, ...